Vascular Endothelial Growth Factor, Recombinant, Human (VEGF, Vascular Endothelial Growth Factor A, VEGFA, VEGF-A, MGC70609, MVCD1, Vascular Permeability Factor, VPF)

Source: \nRecombinant corresponding to 165aa of human Vascular Endothelial Growth Factor expressed in E.coli is a double, non-glycosylated, polypeptide chain.\n\nMolecular Weight: \n~38.2kD\n\nBiological Activity:\nThe biological activity is determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 1.0-8.0 nug/ml.\n\nDimers and Aggregates:\n(same/less than)1% (SDS-PAGE)\n\nProtein Content:\nProtein quantitation was carried out by two independent methods:1. UV spectroscopy at 280nm using the absorbency value of 0.2875 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENEcomputer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a calibrated solution of VEGF as a Reference Standard.\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

V2110-15T

Size

2ug

Form

Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to (same/more than)0.1mg/ml.

Purity

~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: (same/less than)0.1ng/ug (IEU/ug)

References

1. VEGF as a therapeutic target in cancer. Oncology 2005;69 Suppl 3:11-6. 2. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69 Suppl 3:4-10. 3. Introduction. Critical role of anti-angiogenesis and VEGF inhibition in colorectal cancer. Oncology 2005;69 Suppl 3:1-3. 4. Biological effects of a software-controlled voltage pulse generator (PhyBack PBK-2C) on the release of vascular endothelial growth factor (VEGF). In Vivo 2005 Nov-Dec;19(6):949-58. 5. Facilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents. Nucleic Acids Res 2005 Oct 20; 33(18):6070-80. 6. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005 Oct;8(4):299-309.